Preparation of Powdered Fish Oil as a Sustained-Release Formulation

被引：0

作者：

Aoki, Shigeta ^{[1
]}

Nakagawa, Kiyotaka ^{[1
]}

Hanzawa, Yasuhiko ^{[1
]}

Matsumoto, Shunsuke ^{[2
]}

Akutsu, Mitsuaki ^{[2
]}

Kimizuka, Norihito ^{[3
]}

Shimoyamada, Makoto ^{[3
]}

Nishikawa, Masazumi ^{[3
]}

Miyazawa, Teruo ^{[1
,4
]}

机构：

[1] Tohoku Univ, Grad Sch Agr Sci, Aoba Ku, Sendai, Miyagi 9818555, Japan

[2] Aoba Kasei CO LTD, Izumi Ku, Sendai, Miyagi 9848642, Japan

[3] Miyagi Univ, Sch Food Agr & Environm Sci, Taihaku Ku, Sendai, Miyagi 9820215, Japan

[4] New Ind Creat Hatchery Ctr NICHe, Aoba Ku, Sendai, Miyagi 9808579, Japan

来源：

JOURNAL OF THE JAPANESE SOCIETY FOR FOOD SCIENCE AND TECHNOLOGY-NIPPON SHOKUHIN KAGAKU KOGAKU KAISHI | 2014年 / 61卷 / 10期

关键词：

powdered fish oil; DHA; EPA; slow-release property; X-RAY-DIFFRACTION; OXIDATIVE STABILITY; CARDIOVASCULAR-DISEASE; DOCOSAHEXAENOIC ACID; DROPLET SIZE; PALM STEARIN; FATTY-ACIDS; CRYSTALLIZATION; OMEGA-3-FATTY-ACIDS; ABSORPTION;

D O I：

10.3136/nskkk.61.467

中图分类号：

TS2 [食品工业];

学科分类号：

0832 ;

摘要：

Focusing on the gelatin/transglutaminase cross-linking reaction, we aimed to develop a preparation method for powdered fish oil as a sustained-release formulation. Various combinations of gelatin (containing transglutaminase) and emulsifiers were screened to obtain a high quality powder. The newly developed powder contained high amounts of lipids (74% of dry weight; 152 mg docosahexaenoic acid/g, 41 mg eicosapentaenoic acid/g); nevertheless, the powder exhibited good oxidation stability. As expected, the powdered fish oil showed slow-release properties in experiments in vitro. This novel powdered fish oil would therefore be useful for nutraceutical applications.

引用

页码：467 / 474

页数：8

共 50 条

[1] Bioavailability of a generic sustained-release formulation of diclofenac compared with the standard sustained-release formulation
Hooper, IT
Allen, E
McLaughlin, K
Ward, C
Sioufi, A
CLINICAL DRUG INVESTIGATION, 1996, 12 (05) : 259 - 270
[2] FORMULATION OF TABLETS WITH SUSTAINED-RELEASE
SALOMON, JL
DOELKER, E
PHARMACEUTICA ACTA HELVETIAE, 1980, 55 (06): : 174 - 182
[3] Preparation and evaluation of a sustained-release formulation of nifedipine HPMC tablets
Yan, G
Li, HN
Zhang, RH
Ding, DR
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2000, 26 (06) : 681 - 686
[4] Formulation study and drug release mechanism of a new theophylline sustained-release preparation
Hayashi, T
Kanbe, H
Okada, M
Suzuki, M
Ikeda, Y
Onuki, Y
Kaneko, T
Sonobe, T
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2005, 304 (1-2) : 91 - 101
[5] A research on aspirin sustained-release formulation
Xu, GJ
Fang, F
Zhang, RH
Sunada, H
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1997, 23 (08) : 741 - 747
[6] SUSTAINED-RELEASE FORMULATION OF SALBUTAMOL SULFATE
MURTHY, RSR
MALHOTRA, M
MIGLANI, BD
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1991, 17 (10) : 1373 - 1380
[7] Sustained-release formulation of sarpogrelate hydrochloride
Hye Jin Kim
Dae Hwan Shin
Eun Ah Lim
Jin-Seok Kim
Archives of Pharmacal Research, 2015, 38 : 35 - 41
[8] BIOAVAILABILITY OF A SUSTAINED-RELEASE DYPHYLLINE FORMULATION
SIMONS, KJ
SIMONS, FER
BIERMAN, CW
JOURNAL OF CLINICAL PHARMACOLOGY, 1977, 17 (04): : 237 - 242
[9] PHARMACOKINETICS OF A SUSTAINED-RELEASE THEOPHYLLINE FORMULATION
TREMBATH, PW
BOOBIS, SW
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 9 (04) : 365 - 369
[10] Optimum formulation for sustained-release insulin
Takenaga, M
Yamaguchi, Y
Kitagawa, A
Ogawa, Y
Kawai, S
Mizushima, Y
Igarashi, R
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 271 (1-2) : 85 - 94

← 1 2 3 4 5 →